文献速递治疗药物监测与药物基因组学特殊人群用药

婴儿急性淋巴细胞白血病大剂量甲氨蝶呤群体药代动力学提示需床旁个体化剂量调整

The Population Pharmacokinetics of High-Dose Methotrexate in Infants with Acute Lymphoblastic Leukemia Highlight the Need for Bedside Individualized Dose Adjustment: A Report from the Children's Oncology Group.
PubMed 文献 · Clin Pharmacokinet · 2019-01-01

本研究基于COG P9407试验中71例婴儿急性淋巴细胞白血病患者的672个甲氨蝶呤血药浓度,建立群体药代动力学模型。最终模型为二室模型加异速增长,体重是唯一协变量。甲氨蝶呤清除率的个体间变异为10.7%,个体内变异高达25.4%。模拟显示21.1%的婴儿可从床旁剂量调整中获益,避免超治疗浓度。

要点

  • 婴儿大剂量甲氨蝶呤清除率个体内变异高达25.4%,需关注治疗浓度波动。
  • 体重是最终模型唯一协变量,采用异速增长二室模型描述。
  • 模拟显示21.1%的婴儿可从床旁剂量调整中获益。

核心结论

  • 婴儿大剂量甲氨蝶呤清除率个体内变异较高,床旁算法可能避免因高变异导致的超治疗浓度。

研究设计与样本

  • 基于COG P9407临床试验中71例婴儿急性淋巴细胞白血病患者,共672个甲氨蝶呤血浆浓度,使用NONMEM 7.4进行群体药代动力学分析。

主要发现

  • 甲氨蝶呤药代动力学最佳描述为二室模型加异速增长,体重是唯一协变量。
  • 清除率个体内变异为25.4%,个体间变异为10.7%,中央分布容积个体间变异为13.2%。
  • 模拟显示21.1%的模拟婴儿可从床旁剂量调整中获益,调整输注期间剂量可避免超治疗浓度。

关键数值与推荐

  • 甲氨蝶呤给药方案为4 g/m2静脉输注,在巩固治疗第4-12周共四个周期。

临床怎么用

  • 对婴儿急性淋巴细胞白血病患者使用大剂量甲氨蝶呤时,可考虑采用床旁算法进行个体化剂量调整以降低超治疗浓度风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Infants with acute lymphoblastic leukemia (ALL) treated with high-dose methotrexate may have reduced methotrexate clearance (CL) due to renal immaturity, which may predispose them to toxicity. OBJECTIVE: The aim of this study was to develop a population pharmacokinetic (PK) model of methotrexate in infants with ALL. METHODS: A total of 672 methotrexate plasma concentrations were obtained from 71 infants enrolled in the Children's Oncology Group (COG) Clinical Trial P9407. Infants received methotrexate 4 g/m2 intravenously for four cycles during weeks 4-12 of intensification. A population PK analysis was performed using NONMEM® version 7.4. The final model was evaluated using a non-parametric bootstrap and a visual predictive check. Simulations were performed to evaluate methotrexate dose and the utility of a bedside algorithm for dose individualization. RESULTS: Methotrexate was best characterized by a two-compartment model with allometric scaling. Weight was the only covariate included in the final model. The coefficient of variation for interoccasion variability (IOV) on CL was relatively high at 25.4%, compared with the interindividual variability for CL and central volume of distribution (10.7% and 13.2%, respectively). Simulations identified that 21.1% of simulated infants benefitted from bedside dose adjustment, and adjustment of methotrexate doses during infusions can avoid supratherapeutic concentrations. CONCLUSION: Infants treated with high-dose methotrexate demonstrated a relatively high degree of IOV in methotrexate CL. The magnitude of IOV in the CL of methotrexate suggests that use of a bedside algorithm may avoid supratherapeutic methotrexate concentrations resulting from high IOV in methotrexate CL.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Beechinor RJ, Thompson PA, Hwang MF, et al. The Population Pharmacokinetics of High-Dose Methotrexate in Infants with Acute Lymphoblastic Leukemia Highlight the Need for Bedside Individualized Dose Adjustment: A Report from the Children's Oncology Group. Clin Pharmacokinet. 2019. PMID: 30810947. doi:10.1007/s40262-018-00734-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。